A novel chordoma xenograft allows in vivo drug testing and reveals the importance of NF-kB signaling in chordoma biology

Matteo M. Trucco, Ola Awad, Breelyn A. Wilky, Seth D. Goldstein, Ruili Huang, Robert L. Walker, Preeti Shah, Varalakshmi Katuri, Naheed Gul, Yuelin J. Zhu, Edward F. McCarthy, Ido Paz-Priel, Paul S. Meltzer, Christopher P. Austin, Menghang Xia, David M. Loeb

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Chordoma is a rare primary bone malignancy that arises in the skull base, spine and sacrum and originates from remnants of the notochord. These tumors are typically resistant to conventional chemotherapy, and to date there are no FDA-approved agents to treat chordoma. The lack of in vivo models of chordoma has impeded the development of new therapies for this tumor. Primary tumor from a sacral chordoma was xenografted into NOD/SCID/IL-2R y-null mice. The xenograft is serially transplantable and was characterized by both gene expression analysis and whole genome SNP genotyping. The NIH Chemical Genomics Center performed high-throughput screening of 2,816 compounds using two established chordoma cell lines, U-CH1 and U-CH2B. The screen yielded several compounds that showed activity and two, sunitinib and bortezomib, were tested in the xenograft. Both agents slowed the growth of the xenograft tumor. Sensitivity to an inhibitor of IkB, as well as inhibition of an NF-kB gene expression signature demonstrated the importance of NF-kB signaling for chordoma growth. This serially transplantable chordoma xenograft is thus a practical model to study chordomas and perform in vivo preclinical drug testing.

Original languageEnglish (US)
Article numbere79950
JournalPLoS One
Volume8
Issue number11
DOIs
StatePublished - Nov 6 2013
Externally publishedYes

Fingerprint

Chordoma
transcription factor NF-kappa B
NF-kappa B
Heterografts
Tumors
Biological Sciences
drugs
neoplasms
Testing
Gene expression
Pharmaceutical Preparations
testing
gene expression
Chemotherapy
spine (bones)
Neoplasms
skull
genotyping
drug therapy
Screening

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

A novel chordoma xenograft allows in vivo drug testing and reveals the importance of NF-kB signaling in chordoma biology. / Trucco, Matteo M.; Awad, Ola; Wilky, Breelyn A.; Goldstein, Seth D.; Huang, Ruili; Walker, Robert L.; Shah, Preeti; Katuri, Varalakshmi; Gul, Naheed; Zhu, Yuelin J.; McCarthy, Edward F.; Paz-Priel, Ido; Meltzer, Paul S.; Austin, Christopher P.; Xia, Menghang; Loeb, David M.

In: PLoS One, Vol. 8, No. 11, e79950, 06.11.2013.

Research output: Contribution to journalArticle

Trucco, MM, Awad, O, Wilky, BA, Goldstein, SD, Huang, R, Walker, RL, Shah, P, Katuri, V, Gul, N, Zhu, YJ, McCarthy, EF, Paz-Priel, I, Meltzer, PS, Austin, CP, Xia, M & Loeb, DM 2013, 'A novel chordoma xenograft allows in vivo drug testing and reveals the importance of NF-kB signaling in chordoma biology', PLoS One, vol. 8, no. 11, e79950. https://doi.org/10.1371/journal.pone.0079950
Trucco, Matteo M. ; Awad, Ola ; Wilky, Breelyn A. ; Goldstein, Seth D. ; Huang, Ruili ; Walker, Robert L. ; Shah, Preeti ; Katuri, Varalakshmi ; Gul, Naheed ; Zhu, Yuelin J. ; McCarthy, Edward F. ; Paz-Priel, Ido ; Meltzer, Paul S. ; Austin, Christopher P. ; Xia, Menghang ; Loeb, David M. / A novel chordoma xenograft allows in vivo drug testing and reveals the importance of NF-kB signaling in chordoma biology. In: PLoS One. 2013 ; Vol. 8, No. 11.
@article{4063b18ec785429ebeb0af8e58f55d3c,
title = "A novel chordoma xenograft allows in vivo drug testing and reveals the importance of NF-kB signaling in chordoma biology",
abstract = "Chordoma is a rare primary bone malignancy that arises in the skull base, spine and sacrum and originates from remnants of the notochord. These tumors are typically resistant to conventional chemotherapy, and to date there are no FDA-approved agents to treat chordoma. The lack of in vivo models of chordoma has impeded the development of new therapies for this tumor. Primary tumor from a sacral chordoma was xenografted into NOD/SCID/IL-2R y-null mice. The xenograft is serially transplantable and was characterized by both gene expression analysis and whole genome SNP genotyping. The NIH Chemical Genomics Center performed high-throughput screening of 2,816 compounds using two established chordoma cell lines, U-CH1 and U-CH2B. The screen yielded several compounds that showed activity and two, sunitinib and bortezomib, were tested in the xenograft. Both agents slowed the growth of the xenograft tumor. Sensitivity to an inhibitor of IkB, as well as inhibition of an NF-kB gene expression signature demonstrated the importance of NF-kB signaling for chordoma growth. This serially transplantable chordoma xenograft is thus a practical model to study chordomas and perform in vivo preclinical drug testing.",
author = "Trucco, {Matteo M.} and Ola Awad and Wilky, {Breelyn A.} and Goldstein, {Seth D.} and Ruili Huang and Walker, {Robert L.} and Preeti Shah and Varalakshmi Katuri and Naheed Gul and Zhu, {Yuelin J.} and McCarthy, {Edward F.} and Ido Paz-Priel and Meltzer, {Paul S.} and Austin, {Christopher P.} and Menghang Xia and Loeb, {David M.}",
year = "2013",
month = "11",
day = "6",
doi = "10.1371/journal.pone.0079950",
language = "English (US)",
volume = "8",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "11",

}

TY - JOUR

T1 - A novel chordoma xenograft allows in vivo drug testing and reveals the importance of NF-kB signaling in chordoma biology

AU - Trucco, Matteo M.

AU - Awad, Ola

AU - Wilky, Breelyn A.

AU - Goldstein, Seth D.

AU - Huang, Ruili

AU - Walker, Robert L.

AU - Shah, Preeti

AU - Katuri, Varalakshmi

AU - Gul, Naheed

AU - Zhu, Yuelin J.

AU - McCarthy, Edward F.

AU - Paz-Priel, Ido

AU - Meltzer, Paul S.

AU - Austin, Christopher P.

AU - Xia, Menghang

AU - Loeb, David M.

PY - 2013/11/6

Y1 - 2013/11/6

N2 - Chordoma is a rare primary bone malignancy that arises in the skull base, spine and sacrum and originates from remnants of the notochord. These tumors are typically resistant to conventional chemotherapy, and to date there are no FDA-approved agents to treat chordoma. The lack of in vivo models of chordoma has impeded the development of new therapies for this tumor. Primary tumor from a sacral chordoma was xenografted into NOD/SCID/IL-2R y-null mice. The xenograft is serially transplantable and was characterized by both gene expression analysis and whole genome SNP genotyping. The NIH Chemical Genomics Center performed high-throughput screening of 2,816 compounds using two established chordoma cell lines, U-CH1 and U-CH2B. The screen yielded several compounds that showed activity and two, sunitinib and bortezomib, were tested in the xenograft. Both agents slowed the growth of the xenograft tumor. Sensitivity to an inhibitor of IkB, as well as inhibition of an NF-kB gene expression signature demonstrated the importance of NF-kB signaling for chordoma growth. This serially transplantable chordoma xenograft is thus a practical model to study chordomas and perform in vivo preclinical drug testing.

AB - Chordoma is a rare primary bone malignancy that arises in the skull base, spine and sacrum and originates from remnants of the notochord. These tumors are typically resistant to conventional chemotherapy, and to date there are no FDA-approved agents to treat chordoma. The lack of in vivo models of chordoma has impeded the development of new therapies for this tumor. Primary tumor from a sacral chordoma was xenografted into NOD/SCID/IL-2R y-null mice. The xenograft is serially transplantable and was characterized by both gene expression analysis and whole genome SNP genotyping. The NIH Chemical Genomics Center performed high-throughput screening of 2,816 compounds using two established chordoma cell lines, U-CH1 and U-CH2B. The screen yielded several compounds that showed activity and two, sunitinib and bortezomib, were tested in the xenograft. Both agents slowed the growth of the xenograft tumor. Sensitivity to an inhibitor of IkB, as well as inhibition of an NF-kB gene expression signature demonstrated the importance of NF-kB signaling for chordoma growth. This serially transplantable chordoma xenograft is thus a practical model to study chordomas and perform in vivo preclinical drug testing.

UR - http://www.scopus.com/inward/record.url?scp=84892420483&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892420483&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0079950

DO - 10.1371/journal.pone.0079950

M3 - Article

C2 - 24223206

AN - SCOPUS:84892420483

VL - 8

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 11

M1 - e79950

ER -